BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.17.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KESHO
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260806T193000
DTEND;TZID=Africa/Nairobi:20260806T203000
DTSTAMP:20260820T224450Z
CREATED:20260820T224041Z
LAST-MODIFIED:20260820T224450Z
UID:41901-1786044600-1786048200@kesho-kenya.org
SUMMARY:Ovarian Cancer in Focus
DESCRIPTION:Ovarian Cancer in Focus: Innovation\, Care and Evolving Care\n\nModerator: Dr. Amina K. Habib\nSpeaker: Dr. Chris Gallagher\nDate: 6 August 2026\n\nSummary\nThis session examined recent developments in epithelial ovarian cancer\, from the continuing challenge of earlier diagnosis to surgical decision-making\, molecular stratification\, maintenance therapy and emerging options for recurrent and platinum-resistant disease. \nA central theme was the move towards increasingly biomarker-informed care. Dr. Chris Gallagher highlighted how BRCA1/2 mutations and homologous recombination deficiency are shaping treatment selection\, particularly PARP inhibitor maintenance after response to platinum-based chemotherapy. The discussion reinforced that these therapies offer the greatest value when matched to tumour biology rather than applied broadly. \nThe session also explored the challenge of finding ovarian cancer earlier. Emerging approaches using circulating DNA fragments may improve future detection\, but the evidence remains preliminary and requires wider validation. Surgical treatment was similarly framed around careful patient selection: the choice between upfront cytoreductive surgery and neoadjuvant chemotherapy should reflect disease extent\, patient fitness and the likelihood of achieving complete resection. \nFor recurrent and difficult-to-treat disease\, the discussion highlighted newer approaches including folate receptor alpha-targeted antibody-drug conjugates in platinum-resistant ovarian cancer and molecularly targeted strategies for low-grade serous disease. These developments are expanding treatment possibilities\, although the role of immunotherapy remains less clearly established. \nThe discussion brought these advances into the African context\, where access to BRCA and HRD testing\, targeted therapies and newer medicines remains uneven. Molecular testing is most meaningful when it can inform an accessible treatment pathway. In recurrent disease especially\, expected benefit must be weighed against toxicity\, quality of life\, patient fitness and financial burden. \nAcross the session\, a consistent message emerged: ovarian cancer care is becoming increasingly defined by tumour biology\, but improved outcomes still depend on appropriate surgery\, access to molecular testing\, careful patient selection and treatment pathways that reflect both evidence and real-world access. \nKey Takeaways\n\nEarlier detection remains a major unmet need\, with emerging circulating DNA approaches still requiring further validation.\nBRCA and homologous recombination status are increasingly important in guiding treatment selection.\nSurgical sequencing should be individualised\, with complete cytoreduction remaining an important treatment objective.\nPARP inhibitors and newer targeted therapies are expanding options for selected patients\, including those with recurrent or platinum-resistant disease.\nIn African settings\, clinical benefit\, treatment access\, affordability and quality of life must remain central to decision-making.\n\nContinue the learning \nThis summary captures only part of the discussion. To request the full session recording\, contact the KESHO Secretariat. KESHO members can access CME recordings and revisit expert-led sessions across haematology and oncology throughout the year. Join KESHO to access the full CME learning library.
URL:https://kesho-kenya.org/event/ovarian-cancer-in-focus/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/08/Ovarian-Cancer-in-Focus-e1787265870600.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260813T193000
DTEND;TZID=Africa/Nairobi:20260813T203000
DTSTAMP:20260811T142645Z
CREATED:20260811T142028Z
LAST-MODIFIED:20260811T142645Z
UID:41876-1786649400-1786653000@kesho-kenya.org
SUMMARY:From Digital Diagnosis to Connected Cancer Care
DESCRIPTION:“From Digital Diagnosis to Connected Cancer Care” \nCPD ACCREDITED \nDate: 13th August 2026\nTime: 7 PM – 8:30 PM EAT \nSpeaker: Dr. Arvind Rao\nProfessor\, Department of Computational Medicine and Bioinformatics\, University of Michigan\nTalk: “From Digital Diagnosis to AI-Powered Cancer Care: Governance\, LLMs\, and the Connected Future” \nSpeaker: Dr. Joshua Kibera\nAnatomical Pathologist\, CEO/Founder – The Pathology Network\nTalk: “Beyond the Algorithm: Building the Digital Diagnostic Infrastructure for AI-Enabled Precision Cancer Care” \nModerator: Dr. Anne Korir\nSenior Research Scientist\, Kenya Medical Research Institute (KEMRI) \n    	\n        Click to Register
URL:https://kesho-kenya.org/event/from-digital-diagnosis-to-connected-cancer-care/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/08/WhatsApp-Image-2026-08-11-at-10.35.44-AM-e1786457992618.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20261119T080000
DTEND;TZID=Africa/Nairobi:20261121T170000
DTSTAMP:20260602T074510Z
CREATED:20260407T183641Z
LAST-MODIFIED:20260602T074510Z
UID:41566-1795075200-1795280400@kesho-kenya.org
SUMMARY:The 9th Kenya International Cancer Conference
DESCRIPTION:
URL:https://kesho-kenya.org/event/2026-kenya-international-cancer-conference/
CATEGORIES:Conferences,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/04/WhatsApp-Image-2026-06-02-at-10.31.48-AM-e1780386294605.jpeg
END:VEVENT
END:VCALENDAR